Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus

Inclusion Criteria: * Diabetic patients with angina and documented ischemia or patients with documented silent ischemia * Patients who are eligible for intracoronary stenting * Age \>18 years, \<75 ages * De novo lesion * Percent diameter stenosis ≥50% * Reference vessel size ≥ 2.5 mm by visual estimation Exclusion Criteria: * History of bleeding diathesis or coagulopathy * Pregnant state * Known hypersensitivity or contra-indication to contrast agent and heparin * Limited life-expectancy (less than 1 year) * Acute ST elevation myocardial infarction on admission * Characteristics of lesion 1. Left main disease 2. In-stent restenosis 3. Graft vessels * Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3) * Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal * Renal dysfunction, creatinine ≥ 2.0mg/dL * Contraindication to aspirin, clopidogrel or cilostazol * Left ventricular ejection fraction \<30% * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).